ClinicalTrials.gg
TerminatedNCT04157335ORCHIDUpdated Feb 19, 2026Results posted

Efficacy and Safety Study of Benralizumab in Patient With Eosinophilic Chronic Rhinosinusitis With Nasal Polyps (ORCHID)

A Phase 3 interventional study of Benralizumab 30 mg and Matched placebo in Nasal Polyposis and Eosinophilic Chronic Rhinosinusitis, sponsored by AstraZeneca. Terminated at 116 sites in 17 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-02-19.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Why this study was terminated
The study has a double-blind period and an open-label period. The study did not meet its primary endpoints after the primary LSLV and the decision was taken to terminate the study early.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
295
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 46 studies in Nasal Polyps with a site in China — 17 open to participants now, 24 under way, 7 of them phase 3. Nasal Polyps · China.

Enrollment
4th of 43
295 · median 90
Started
2019
the only one that year
Phase 3
14 of 46
3 open now
Registered
7th of 46
by date
Lead sponsor
4 of 46
AstraZeneca

Among the 46 studies in Nasal Polyps with a site in China, this one is the 4th largest by enrollment of the 43 interventional ones that give a count, is the only one that started in 2019, is one of 14 in phase 3, and was the 7th registered.

Nasal Polyps

236 studies on the registry are indexed under Nasal Polyps; 68 are open to participants now.

Browse Nasal Polyps studies →

Open to participants now

17 of the 46 studies in Nasal Polyps with a site in China are open now. Recruiting first, the newest first:

12 more — sign in →

All 17 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 40 Nasal Polyps studies recruiting now, 22 (55%) set no upper age limit and 12 (30%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies in Nasal Polyps with a site in China, or all of them as a file.
02

Study summary

This is a randomized, double-blind, placebo-controlled, parallel-group, international, multicenter, Phase 3 study to evaluate the efficacy and safety of repeat dosing of benralizumab 30 mg administered subcutaneously (SC) versus placebo in patients with severe nasal polyposis.

Read the detailed description

Approximately 250 patients will be randomized to receive benralizumab 30 mg SC or matching placebo. After enrolment, eligible patients will enter a 6-week screening/run in period. Patients who meet eligibility criteria will be randomised 1:1 at Week 0 (Day 0) to receive either placebo or benralizumab 30 mg SC every 4 weeks for the first 3 doses (Weeks 0, 4 and 8) and every 8 weeks thereafter (Weeks 16, 24, 32, 40 and 48). An end of treatment visit will be conducted at Week 56.All patients who complete the 56-week DB treatment period on investigational product (IP) may be eligible to continue into around one year OLE (Open Label Extension), during which all patients will receive 8 doses of benralizumab 30 mg. Patients in Benra arm during DB period will receive one dummy dose for the second dose during OLE (Open Label Extension). The last study visit will occur at 8 weeks after the last dose of IP (Week 112/FU). Patients who do not enter OLE (Open Label Extension), will have their last study visit at Week 56 (EoDB) for follow-up and without administration of IP.

03

Conditions studied

  • Nasal Polyposis
  • Eosinophilic Chronic Rhinosinusitis

Keywords

  • Benralizumab
  • Eosinophilic Chronic Rhinosinusitis with Nasal Polyps
  • Nasal Polyps
  • Asthma
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Female or male patients aged 18 to 75 years inclusive
  2. Stable Intranasal (INCS) use for at least 4 weeks prior to enrolment and throughout screening and DB period
  3. History of treatment with systemic corticosteroids (SCS) or prior surgery for CRSwNP
  4. Bilateral sinonasal polyposis with a nasal polyp score (NPS) of 5 at enrolment and randomization (unilateral score of at least 2 for each nostril)
  5. Ongoing symptoms for at least 12 weeks prior to enrolment
  6. Patient-reported moderate to severe nasal blockage score (NBS) ≥2 at enrolment
  7. Bi-weekly mean NBS ≥ 1.5 at randomization
  8. SNOT-22 total score ≥ 20 at enrolment and randomization
  9. Documented physician-diagnosed asthma
  10. Blood eosinophil count of >2% or ≥150/μL at enrolment
  11. LMS E≥M for Asian

Exclusion criteria

Exclusion criteria:

  1. Any nasal and/or sinus surgery within 3 months prior to enrolment
  2. Patients with conditions that makes them non evaluable for the co-primary efficacy endpoint including but not limited to:

    • Unilateral antrochoanal polyps
    • Nasal septal deviation that occludes at least one nostril
    • Current rhinitis medicamentosa
    • Allergic fungal rhinosinusitis or allergic fungal sinusitis;
  3. comorbidities (other eosinophil-driven diseases but CRSwNP) that may put the patient at risk, or may confound interpretation of clinical efficacy and/or safety results
  4. Receipt of SCS for within 4 weeks prior to screening, or a scheduled SCS treatment during the study period.
  5. Receipt of any marketed or biologic product within 6 months of enrolment
  6. Currently pregnant or breastfeeding
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
295 participants (actual)

Study arms

  • Experimental
    Benralizumab

    Benralizumab administered subcutaneously

    Biological: Benralizumab 30 mg

  • Placebo comparator
    Placebo

    Placebo administered subcutaneously

    Biological: Matched placebo

Interventions

  • Benralizumab is 30 mg/ml solution for injection in accessorized pre-filled syringe, 1 ml fill volume. Benralizumab 30 mg subcutaneously will be injected every 4 weeks for the first 3 doses (Weeks 0, 4 and 8) and every 8 weeks thereafter (Weeks 16, 24, 32, 40 and 48). For OLE, Benralizumab 30 mg subcutaneously will be injected every 4 weeks for the first 3 doses and every 8 weeks for the rest 5 doses. For the patients on Benralizumab treatment during double blind period, placebo will be dosed at the second dose during OLE.

  • BiologicalMatched placebo

    Matching placebo solution for injection in accessorized pre-filled syringe. 1 ml fill volume. Matching placebo subcutaneously will be injected every 4 weeks for the first 3 doses (Weeks 0, 4 and 8) and every 8 weeks thereafter (Weeks 16, 24, 32, 40 and 48).

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Endoscopic Total Nasal Polyp Score (NPS) at Week 56

    The total nasal polyp score (NPS) is the sum of the right and left nostril scores (maximum of 8), as evaluated by nasal endoscopy. Higher scores indicate greater symptom severity. The left and right score will be based on a central read with a scale from 0 to 4. Each nasal endoscopy is evaluated by two independent physician reviewers.

    Time frame: Baseline to Week 56

  2. Change From Baseline in Mean Nasal Blockage Score (NBS) at Week 56.

    The NBS is an item in the NPSD. Patients were asked to rate the severity of their worst nasal blockage over the past 24 hours using the following response options: 0 - none; 1 - mild; 2 - moderate; 3 - severe. Higher scores indicate greater symptom severity. The NBS and the changes from baseline were summarised every two weeks (bi-weekly). Baseline was the average of daily responses from Day -13 to Day 1. Bi-weekly mean were calculated if at least 8 days in each 14-day period had evaluable data; otherwise, the biweekly mean was set to missing.

    Time frame: Baseline to week 56

Secondary outcomes

  1. Change From Baseline in Difficulty With Sense of Smell (DSS) Score at Week 56.

    The DSS is an item in the NPSD. Patients were asked to rate the severity of their worst difficulty with sense of smell over the past 24 hours using the following response options: 0-none; 1-mild; 2-moderate; 3-severe. Higher scores indicate greater symptom severity. The DSS and the changes from baseline were summarised every two weeks (bi-weekly). Baseline was the average of daily responses from Day -13 to Day 1. Bi-weekly mean of DSS was calculated if at least 8 days in each 14-day period have evaluable data; otherwise the bi-weekly mean was set to missing.

    Time frame: Baseline to Week 56

  2. Sinus Opacification by CT Scan at Week 56.

    Change from baseline in Lund- Mackay score (LMS). The Lund-Mackay score scoring system is used to provide a quantitative assessment of nasal sinuses on sinus CT scans. Based on the sinus CT images, the five sinuses (maxillary, anterior ethmoid, posterior ethmoid, sphenoid and frontal) on each site are score by central radiologist as follows: (0-Normal; 1-Partial Opacification; 2-Total Opacification). The osteomeatal complex is scored for right and left sides (0 - Not occluded; 2- Occluded). The total score ranges from 0 to 24 (higher scores indicate poorer outcomes).

    Time frame: Baseline to Week 56

  3. Disease Specific Health-related Quality of Life (HRQoL): Change From Baseline in SinoNasal Outcome Test (SNOT-22) Score at Week 56.

    SinoNasal Outcome Test 22 scores are participant-reported and assess physical problems, functional limitations and emotional consequences of SinoNasal conditions. Patient-reported symptom severity and symptom impact over the past 2 weeks are captured via a 6-point scale (0-No Problem to 5-Problem as bad as it can be). The total score is the sum of item scores and has a range from 0 to 110 (higher scores indicate poorer outcomes).

    Time frame: Baseline to Week 56

  4. Time to First Nasal Polyp Surgery

    Time to the first surgery for CRSwNP= Start date of the first surgery for CRSwNP - date of randomisation + 1

    Time frame: Baseline to Week 56

  5. Time to First SCS Course for CRSwNP

    Time to the first SCS use for CRSwNP = Start date of the first SCS use for CRSwNP - date of randomisation + 1

    Time frame: Baseline to Week 56

  6. Time to First NP Surgery and/or SCS Use for CRSwNP

    Time to first surgery and/or SCS use for CRSwNP = earlier date of (start date of first surgery for CRSwNP, start date of first SCS use for CRSwNP) - date of randomisation + 1

    Time frame: Baseline to Week 56

  7. Change From Baseline in Bi-weekly Mean Nasal Polyps Symptom Diary Total Symptom Score at Week 56.

    The participant completed the nasal polyposis symptom diary each morning throughout the study. The participant was asked to consider their experience with nasal polyposis/nasal polyps over the past 24 hours when responding to each question. Participants were asked to report their experience with nasal polyposis symptoms (nasal blockage, nasal congestion, runny nose, postnasal drip (mucus drainage down the throat), headache, facial pain, facial pressure, difficulty with sense of smell). Participants reported the severity of each symptom and symptom impact at its worst using a 4-point verbal rating scale (0-None to 3-Severe). A total symptom score (range from 0 to 24) was calculated by taking the sum of the 8 equally weighted symptom items. Higher scores indicate greater symptom severity.

    Time frame: Baseline to Week 56

  8. Percentage of Participants With Surgery and/or Use SCS for CRSwNP

    Nasal polyps surgery is defined as any procedure involving instruments resulting in incision and removal of tissue (e.g. polypectomy, endoscopic sinus surgery). An SCS course can be considered as a new course if the start date is preceded by at least 7 days after the end date of the last SCS course for CRSwNP (i.e. start date of the new course - end date of the last course \> 7)

    Time frame: Baseline to Week 56

  9. Percentage of Participants With Surgery for CRSwNP

    Nasal polyps surgery is defined as any procedure involving instruments resulting in incision and removal of tissue (e.g. polypectomy, endoscopic sinus surgery).

    Time frame: Baseline to Week 56

  10. Percentage of Participants With SCS Use for CRSwNP

    An SCS course can be considered as a new course if the start date is preceded by at least 7 days after the end date of the last SCS course for CRSwNP (i.e. start date of the new course - end date of the last course \> 7)

    Time frame: Baseline to Week 56

07

Results

Posted Feb 19, 2026

Participant flow

A total of 723 participants were screened between 15NOV2019 and 01JUN2023. Of those, 295 were randomized to either the treatment (147 participants) or placebo (148 participants) arms of the double-blind treatment period. Eight participants were excluded due to Japan GCP breach. Therefore, 144 participants started in the treatment arm and 143 in the placebo arm, for a total of 287 participants.

Double-Blind Period
Participant flow — Double-Blind Period
MilestoneDouble Blind BenralizumabDouble Blind Placebo
Started144143
Completed129130
Not completed1513
Withdrew: Ip discontinuation11
Withdrew: Withdrawal by subject96
Withdrew: Pregnancy10
Withdrew: Physician decision12
Withdrew: Lost to follow-up02
Withdrew: Adverse event11
Withdrew: Site closure20
Withdrew: Patient did not meet randomization criteria01
Open-Label Extension Period
Participant flow — Open-Label Extension Period
MilestoneDouble Blind BenralizumabDouble Blind Placebo
Started122125
Completed8086
Not completed4239
Withdrew: Study terminated by sponsor1926
Withdrew: Withdrawal by subject186
Withdrew: Physician decision32
Withdrew: Adverse event13
Withdrew: Patient withdrew due to failure of treatment12

Outcome measures

PrimaryChange From Baseline in Endoscopic Total Nasal Polyp Score (NPS) at Week 56

The total nasal polyp score (NPS) is the sum of the right and left nostril scores (maximum of 8), as evaluated by nasal endoscopy. Higher scores indicate greater symptom severity. The left and right score will be based on a central read with a scale from 0 to 4. Each nasal endoscopy is evaluated by two independent physician reviewers.

Time frame:
Baseline to Week 56
Reported as:
Mean · Score
Change From Baseline in Endoscopic Total Nasal Polyp Score (NPS) at Week 56
ScoreDouble Blind BenralizumabDouble Blind Placebo
Change From Baseline in Endoscopic Total Nasal Polyp Score (NPS) at Week 56-0.3 ± 1.6-0.1 ± 1.3
Statistical analysis
  • Double Blind Benralizumab vs Double Blind Placebo · ANCOVA · p = 0.1707 · Difference in least squares means: -0.247 · 95% CI -0.599 to 0.106Model: Change from baseline in NPS = Treatment + Region + Baseline BMI + Baseline total NPS
PrimaryChange From Baseline in Mean Nasal Blockage Score (NBS) at Week 56.

The NBS is an item in the NPSD. Patients were asked to rate the severity of their worst nasal blockage over the past 24 hours using the following response options: 0 - none; 1 - mild; 2 - moderate; 3 - severe. Higher scores indicate greater symptom severity. The NBS and the changes from baseline were summarised every two weeks (bi-weekly). Baseline was the average of daily responses from Day -13 to Day 1. Bi-weekly mean were calculated if at least 8 days in each 14-day period had evaluable data; otherwise, the biweekly mean was set to missing.

Time frame:
Baseline to week 56
Reported as:
Mean · Score
Change From Baseline in Mean Nasal Blockage Score (NBS) at Week 56.
ScoreDouble Blind BenralizumabDouble Blind Placebo
Change From Baseline in Mean Nasal Blockage Score (NBS) at Week 56.-0.64 ± 0.98-0.45 ± 0.90
Statistical analysis
  • Double Blind Benralizumab vs Double Blind Placebo · ANCOVA · p = 0.1831 · Difference in least squares means: -0.155 · 95% CI -0.383 to 0.073Model: Change from baseline in bi-weekly mean NBS = Treatment + Region + Baseline BMI + baseline bi-weekly mean NBS
SecondaryChange From Baseline in Difficulty With Sense of Smell (DSS) Score at Week 56.

The DSS is an item in the NPSD. Patients were asked to rate the severity of their worst difficulty with sense of smell over the past 24 hours using the following response options: 0-none; 1-mild; 2-moderate; 3-severe. Higher scores indicate greater symptom severity. The DSS and the changes from baseline were summarised every two weeks (bi-weekly). Baseline was the average of daily responses from Day -13 to Day 1. Bi-weekly mean of DSS was calculated if at least 8 days in each 14-day period have evaluable data; otherwise the bi-weekly mean was set to missing.

Time frame:
Baseline to Week 56
Reported as:
Mean · Score
Change From Baseline in Difficulty With Sense of Smell (DSS) Score at Week 56.
ScoreDouble Blind BenralizumabDouble Blind Placebo
Change From Baseline in Difficulty With Sense of Smell (DSS) Score at Week 56.-0.26 ± 0.78-0.05 ± 0.56
Statistical analysis
  • Double Blind Benralizumab vs Double Blind Placebo · ANCOVA · p = 0.0196 (The p-value is unadjusted.) · Difference in least squares means: -0.191 · 95% CI -0.351 to -0.031Model: Change from baseline in NPS = Treatment + Region + Baseline BMI + baseline bi-weekly mean DSS
SecondarySinus Opacification by CT Scan at Week 56.

Change from baseline in Lund- Mackay score (LMS). The Lund-Mackay score scoring system is used to provide a quantitative assessment of nasal sinuses on sinus CT scans. Based on the sinus CT images, the five sinuses (maxillary, anterior ethmoid, posterior ethmoid, sphenoid and frontal) on each site are score by central radiologist as follows: (0-Normal; 1-Partial Opacification; 2-Total Opacification). The osteomeatal complex is scored for right and left sides (0 - Not occluded; 2- Occluded). The total score ranges from 0 to 24 (higher scores indicate poorer outcomes).

Time frame:
Baseline to Week 56
Reported as:
Mean · Score
Sinus Opacification by CT Scan at Week 56.
ScoreDouble Blind BenralizumabDouble Blind Placebo
Sinus Opacification by CT Scan at Week 56.-1.3 ± 3.4-0.7 ± 3.5
Statistical analysis
  • Double Blind Benralizumab vs Double Blind Placebo · ANCOVA · p = 0.1456 · Difference in least squares means: -0.663 · 95% CI -1.559 to 0.232Model: Change from baseline in LMS = Treatment + Region + Baseline BMI + baseline LMS
SecondaryDisease Specific Health-related Quality of Life (HRQoL): Change From Baseline in SinoNasal Outcome Test (SNOT-22) Score at Week 56.

SinoNasal Outcome Test 22 scores are participant-reported and assess physical problems, functional limitations and emotional consequences of SinoNasal conditions. Patient-reported symptom severity and symptom impact over the past 2 weeks are captured via a 6-point scale (0-No Problem to 5-Problem as bad as it can be). The total score is the sum of item scores and has a range from 0 to 110 (higher scores indicate poorer outcomes).

Time frame:
Baseline to Week 56
Reported as:
Mean · Score
Disease Specific Health-related Quality of Life (HRQoL): Change From Baseline in SinoNasal Outcome Test (SNOT-22) Score at Week 56.
ScoreDouble Blind BenralizumabDouble Blind Placebo
Disease Specific Health-related Quality of Life (HRQoL): Change From Baseline in SinoNasal Outcome Test (SNOT-22) Score at Week 56.-18.0 ± 29.6-15.2 ± 26.6
Statistical analysis
  • Double Blind Benralizumab vs Double Blind Placebo · ANCOVA · p = 0.5844 · Difference in least squares means: -1.783 · 95% CI -8.171 to 4.606Model: Change from baseline in SNOT-22 = Treatment + Region + Baseline BMI + baseline SNOT-22 score
SecondaryTime to First Nasal Polyp Surgery

Time to the first surgery for CRSwNP= Start date of the first surgery for CRSwNP - date of randomisation + 1

Time frame:
Baseline to Week 56
Reported as:
Median · Months
Time to First Nasal Polyp Surgery
MonthsDouble Blind BenralizumabDouble Blind Placebo
Time to First Nasal Polyp Surgery6.31 (3.3 to 10.5)7.79 (4.4 to 12.4)
Statistical analysis
  • Double Blind Benralizumab vs Double Blind Placebo · Regression, Cox · p = 0.6776 (This endpoint was not a part of the pre-specified testing strategy and was not multiplicity protected. The p-value was considered nominal.) · Hazard ratio (hr): 0.82 · 95% CI 0.31 to 2.09A hazard ratio less than 1 indicates a lower rate of incidence for subjects on Benralizumab.
SecondaryTime to First SCS Course for CRSwNP

Time to the first SCS use for CRSwNP = Start date of the first SCS use for CRSwNP - date of randomisation + 1

Time frame:
Baseline to Week 56
Reported as:
Median · Months
Time to First SCS Course for CRSwNP
MonthsDouble Blind BenralizumabDouble Blind Placebo
Time to First SCS Course for CRSwNP5.62 (0.1 to 13.0)6.37 (0.1 to 11.4)
Statistical analysis
  • Double Blind Benralizumab vs Double Blind Placebo · Regression, Cox · p = 0.8033 (This endpoint was not a part of the pre-specified testing strategy and was not multiplicity protected. The p-value was considered nominal.) · Hazard ratio (hr): 0.93 · 95% CI 0.51 to 1.69A hazard ratio less than 1 indicates a lower rate of incidence for subjects on Benralizumab.
SecondaryTime to First NP Surgery and/or SCS Use for CRSwNP

Time to first surgery and/or SCS use for CRSwNP = earlier date of (start date of first surgery for CRSwNP, start date of first SCS use for CRSwNP) - date of randomisation + 1

Time frame:
Baseline to Week 56
Reported as:
Median · Months
Time to First NP Surgery and/or SCS Use for CRSwNP
MonthsDouble Blind BenralizumabDouble Blind Placebo
Time to First NP Surgery and/or SCS Use for CRSwNP5.70 (0.1 to 13.0)6.37 (0.1 to 12.4)
Statistical analysis
  • Double Blind Benralizumab vs Double Blind Placebo · Regression, Cox · p = 0.5226 (This endpoint was not a part of the pre-specified testing strategy and was not multiplicity protected. The p-value was considered nominal.) · Hazard ratio (hr): 0.84 · 95% CI 0.49 to 1.43A hazard ratio less than 1 indicates a lower rate of incidence for subjects on Benralizumab.
SecondaryChange From Baseline in Bi-weekly Mean Nasal Polyps Symptom Diary Total Symptom Score at Week 56.

The participant completed the nasal polyposis symptom diary each morning throughout the study. The participant was asked to consider their experience with nasal polyposis/nasal polyps over the past 24 hours when responding to each question. Participants were asked to report their experience with nasal polyposis symptoms (nasal blockage, nasal congestion, runny nose, postnasal drip (mucus drainage down the throat), headache, facial pain, facial pressure, difficulty with sense of smell). Participants reported the severity of each symptom and symptom impact at its worst using a 4-point verbal rating scale (0-None to 3-Severe). A total symptom score (range from 0 to 24) was calculated by taking the sum of the 8 equally weighted symptom items. Higher scores indicate greater symptom severity.

Time frame:
Baseline to Week 56
Reported as:
Mean · Score
Change From Baseline in Bi-weekly Mean Nasal Polyps Symptom Diary Total Symptom Score at Week 56.
ScoreDouble Blind BenralizumabDouble Blind Placebo
Change From Baseline in Bi-weekly Mean Nasal Polyps Symptom Diary Total Symptom Score at Week 56.-3.19 ± 5.78-2.32 ± 5.83
Statistical analysis
  • Double Blind Benralizumab vs Double Blind Placebo · ANCOVA · p = 0.2201 (This endpoint was not a part of the pre-specified testing strategy and was not multiplicity protected. The p-value was considered nominal.) · Difference in least squares means: -0.860 · 95% CI -2.235 to 0.515Model: Change from baseline in NPSD TSS = Treatment + Region + Baseline BMI + baseline NPSD TSS
SecondaryPercentage of Participants With Surgery and/or Use SCS for CRSwNP

Nasal polyps surgery is defined as any procedure involving instruments resulting in incision and removal of tissue (e.g. polypectomy, endoscopic sinus surgery). An SCS course can be considered as a new course if the start date is preceded by at least 7 days after the end date of the last SCS course for CRSwNP (i.e. start date of the new course - end date of the last course \> 7)

Time frame:
Baseline to Week 56
Reported as:
Count of participants · Participants
Percentage of Participants With Surgery and/or Use SCS for CRSwNP
ParticipantsDouble Blind BenralizumabDouble Blind Placebo
Percentage of Participants With Surgery and/or Use SCS for CRSwNP2630
Statistical analysis
  • Double Blind Benralizumab vs Double Blind Placebo · Cochran-Mantel-Haenszel · p = 0.5130 (This endpoint was not a part of the pre-specified testing strategy and was not multiplicity protected. The p-value was considered nominal.) · Odds ratio (or): 0.82 · 95% CI 0.45 to 1.48An odds ratio less than 1 favors Benralizumab.
SecondaryPercentage of Participants With Surgery for CRSwNP

Nasal polyps surgery is defined as any procedure involving instruments resulting in incision and removal of tissue (e.g. polypectomy, endoscopic sinus surgery).

Time frame:
Baseline to Week 56
Reported as:
Count of participants · Participants
Percentage of Participants With Surgery for CRSwNP
ParticipantsDouble Blind BenralizumabDouble Blind Placebo
Percentage of Participants With Surgery for CRSwNP810
Statistical analysis
  • Double Blind Benralizumab vs Double Blind Placebo · Cochran-Mantel-Haenszel · p = 0.5662 (This endpoint was not a part of the pre-specified testing strategy and was not multiplicity protected. The p-value was considered nominal.) · Odds ratio (or): 0.75 · 95% CI 0.28 to 1.99An odds ratio less than 1 favors Benralizumab.
SecondaryPercentage of Participants With SCS Use for CRSwNP

An SCS course can be considered as a new course if the start date is preceded by at least 7 days after the end date of the last SCS course for CRSwNP (i.e. start date of the new course - end date of the last course \> 7)

Time frame:
Baseline to Week 56
Reported as:
Count of participants · Participants
Percentage of Participants With SCS Use for CRSwNP
ParticipantsDouble Blind BenralizumabDouble Blind Placebo
Percentage of Participants With SCS Use for CRSwNP2122
Statistical analysis
  • Double Blind Benralizumab vs Double Blind Placebo · Cochran-Mantel-Haenszel · p = 0.8454 (This endpoint was not a part of the pre-specified testing strategy and was not multiplicity protected. The p-value was considered nominal.) · Odds ratio (or): 0.94 · 95% CI 0.49 to 1.81An odds ratio less than 1 favors Benralizumab.

Adverse events

Collected over On study AEs were collected from the first dose to the last date in study, up to 112 weeks.. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Double Blind Benralizumab0/144 (0%)12/144 (8.3%)78/144 (54.2%)
Double Blind Placebo0/143 (0%)12/143 (8.4%)59/143 (41.3%)
Double Blind Benralizumab First, Then Open Label Benralizumab0/122 (0%)6/122 (4.9%)37/122 (30.3%)
Double Blind Placebo First, Then Open Label Benralizumab0/125 (0%)9/125 (7.2%)33/125 (26.4%)
Most frequent serious events
Showing 10 of 34
Most frequent serious events
EventDouble Blind BenralizumabDouble Blind PlaceboDouble Blind Benralizumab First, Then Open Label BenralizumabDouble Blind Placebo First, Then Open Label Benralizumab
COVID-19 pneumoniaInfections and infestations0/1440/1432/1221/125
PneumoniaInfections and infestations0/1442/1430/1221/125
InfluenzaInfections and infestations0/1440/1431/1220/125
Lower respiratory tract infectionInfections and infestations0/1441/1431/1221/125
Meniscus injuryInjury, poisoning and procedural complications0/1440/1431/1220/125
Invasive breast carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1440/1431/1220/125
Chronic rhinosinusitis with nasal polypsRespiratory, thoracic and mediastinal disorders0/1440/1431/1221/125
Infective exacerbation of asthmaInfections and infestations0/1440/1430/1221/125
ArthralgiaMusculoskeletal and connective tissue disorders0/1440/1430/1221/125
OsteoarthritisMusculoskeletal and connective tissue disorders0/1440/1430/1221/125
Most frequent other events
Showing 10 of 12
Most frequent other events
EventDouble Blind BenralizumabDouble Blind PlaceboDouble Blind Benralizumab First, Then Open Label BenralizumabDouble Blind Placebo First, Then Open Label Benralizumab
AsthmaRespiratory, thoracic and mediastinal disorders16/14422/1437/1228/125
COVID-19Infections and infestations22/14416/1439/1227/125
Upper respiratory tract infectionInfections and infestations13/14414/1439/1224/125
NasopharyngitisInfections and infestations11/1449/1439/1228/125
HeadacheNervous system disorders11/1447/1431/1224/125
Back painMusculoskeletal and connective tissue disorders7/1441/1431/1222/125
Influenza like illnessGeneral disorders7/1444/1432/1220/125
PyrexiaGeneral disorders7/1443/1431/1224/125
ArthralgiaMusculoskeletal and connective tissue disorders2/1446/1432/1223/125
Chronic gastritisGastrointestinal disorders6/1441/1430/1222/125

Baseline characteristics

All participants who were randomized and received any IP were included in the full analysis set.

Age, Categorical
Age, Categorical(Participants)Double Blind BenralizumabDouble Blind PlaceboTotal
<=18 years000
Between 18 and 65 years128126254
>=65 years161733
Age, Continuous
Age, Continuous(Years)Double Blind BenralizumabDouble Blind PlaceboTotal
Mean49.5 ± 12.749.8 ± 12.749.6 ± 12.7
Sex: Female, Male
Sex: Female, Male(Participants)Double Blind BenralizumabDouble Blind PlaceboTotal
Female6154115
Male8389172
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Double Blind BenralizumabDouble Blind PlaceboTotal
White7773150
Black or African American022
Asian6666132
American Indian or Alaska Native000
Native Hawaiian or Other Pacific Islander000
Other123
08

Study locations

116 sites
  • Research Site
    Huntington Beach, California 92647, United States
  • Research Site
    Grand Junction, Colorado 81501, United States
  • Research Site
    Gainesville, Florida 32605, United States
  • Research Site
    Louisville, Kentucky 40220, United States
  • Research Site
    White Marsh, Maryland 21162, United States
  • Research Site
    The Bronx, New York 10461, United States
  • Research Site
    White Plains, New York 10605, United States
  • Research Site
    Tulsa, Oklahoma 74136, United States
  • Research Site
    Bethlehem, Pennsylvania 18017, United States
  • Research Site
    Fort Worth, Texas 76109, United States
  • Research Site
    McKinney, Texas 75070, United States
  • Research Site
    St. George, Utah 84790, United States
  • Research Site
    Richmond, Virginia 23235, United States
  • Research Site
    Bellingham, Washington 98225, United States
  • Research Site
    Milwaukee, Wisconsin 53228, United States
  • Research Site
    Buenos Aires, C1121 ABE, Argentina
  • Research Site
    Buenos Aires, C1414AIF, Argentina
  • Research Site
    Ciudad de Buenos Aire, C1425BEN, Argentina
  • Research Site
    San Fernando, B1646EBJ, Argentina
  • Research Site
    Herston, 4029, Australia
  • Research Site
    Melbourne, 3004, Australia
  • Research Site
    Spearwood, 6163, Australia
  • Research Site
    Brussels, 1200, Belgium
  • Research Site
    Ghent, 9000, Belgium
  • Research Site
    Leuven, 3000, Belgium
  • Research Site
    Plovdiv, 4001, Bulgaria
  • Research Site
    Sofia, 1303, Bulgaria
  • Research Site
    Sofia, 1606, Bulgaria
  • Research Site
    Quillota, 2260000, Chile
  • Research Site
    Santiago, 7500588, Chile
  • Research Site
    Santiago, 8150000, Chile
  • Research Site
    Talca, 3481349, Chile
  • Research Site
    Beijing, 100044, China
  • Research Site
    Beijing, 100191, China
  • Research Site
    Beijing, 100730, China
  • Research Site
    Changchun, 130061, China
  • Research Site
    Changsha, 410008, China
  • Research Site
    Changsha, 410013, China
  • Research Site
    Changsha, China
  • Research Site
    Chengdu, 610041, China
  • Research Site
    Chengdu, 610072, China
  • Research Site
    Chongqing, 400042, China
  • Research Site
    Foshan, 528000, China
  • Research Site
    Guangzhou, 510000, China
  • Research Site
    Guangzhou, 510180, China
  • Research Site
    Hangzhou, 310003, China
  • Research Site
    Jinan, 250014, China
  • Research Site
    Nanchang, 330006, China
  • Research Site
    Nanjing, 210029, China
  • Research Site
    Nanning, 530021, China
  • Research Site
    Qingdao, 266071, China
  • Research Site
    Shanghai, 200065, China
  • Research Site
    Shanghai, 200092, China
  • Research Site
    Tianjin, 300050, China
  • Research Site
    Ürümqi, 830054, China
  • Research Site
    Wuhan, 430022, China
  • Research Site
    Xi'an, 710004, China
  • Research Site
    Xi'an, 710061, China
  • Research Site
    Yantai, 264000, China
  • Research Site
    Marseille, 13005, France
  • Research Site
    Toulouse, 31059, France
  • Research Site
    Budapest, 1033, Hungary
  • Research Site
    Budapest, 1046, Hungary
  • Research Site
    Győr, 9024, Hungary
  • Research Site
    Kaposvár, 7400, Hungary
  • Research Site
    Siófok, 8600, Hungary
  • Research Site
    Székesfehérvár, 8000, Hungary
  • Research Site
    Tatabánya, 2800, Hungary
  • Research Site
    Catanzaro, 88100, Italy
  • Research Site
    Pisa, 56124, Italy
  • Research Site
    Roma, 00161, Italy
  • Research Site
    Roma, 00168, Italy
  • Research Site
    Chiba, 262-0015, Japan
  • Research Site
    Fujisawa-shi, 251-0052, Japan
  • Research Site
    Hiroshima, 734-8551, Japan
  • Research Site
    Ichikawa-shi, 272-0143, Japan
  • Research Site
    Iida-shi, 395-8505, Japan
  • Research Site
    Kawasaki-shi, 211-0063, Japan
  • Research Site
    Kumamoto, 860-0814, Japan
  • Research Site
    Meguro-ku, 153-0061, Japan
  • Research Site
    Meguro-ku, 153-8515, Japan
  • Research Site
    Minatoku, 105-8471, Japan
  • Research Site
    Moriguchi-shi, 570-0074, Japan
  • Research Site
    Nagaoka-shi, 940-2085, Japan
  • Research Site
    Osaka, 540-0008, Japan
  • Research Site
    Shinjuku-ku, 160-0017, Japan
  • Research Site
    Yoshida-gun, 910-1193, Japan
  • Research Site
    Bydgoszcz, 85-231, Poland
  • Research Site
    Elblag, 82-300, Poland
  • Research Site
    Krakow, 31-513, Poland
  • Research Site
    Lublin, 20-552, Poland
  • Research Site
    Nadarzyn, 05-830, Poland
  • Research Site
    Poznan, 60-805, Poland
  • Research Site
    Wroclaw, 53-301, Poland
  • Research Site
    Łodź, 90-153, Poland
  • Research Site
    Izhevsk, 426061, Russia
  • Research Site
    Penza, 440067, Russia
  • Research Site
    Saint Petersburg, 196158, Russia
  • Research Site
    Taipei, 10002, Taiwan
  • Research Site
    Taipei, 110, Taiwan

Showing the first 100 of 116 sites across 17 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Chong LY, Piromchai P, Sharp S, Snidvongs K, Webster KE, Philpott C, Hopkins C, Burton MJ. Biologics for chronic rhinosinusitis. Cochrane Database Syst Rev. 2021 Mar 12;3(3):CD013513. doi: 10.1002/14651858.CD013513.pub3. PubMed 33710614 ↗

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2019 to primary completion in Aug 2024, 56 months.

Results were first posted in Feb 2026, 1 year 6 months after primary completion. A results delay was requested in Aug 2025.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 23, 2019
First posted
Nov 8, 2019
StartActual
Nov 25, 2019
Primary completionActual
Aug 6, 2024
CompletionActual
Apr 7, 2025
Results delay requested
Aug 4, 2025
Results first posted
Feb 19, 2026
Last update
Feb 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04157335
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Nov 8, 2019
Start date
Nov 25, 2019
Primary completion
Aug 6, 2024
Completion
Apr 7, 2025
Results posted
Feb 19, 2026
Last update
Feb 19, 2026

Study contacts

Luo Zhang, Prof. Dr.
principal investigator · Beijing Tongren Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Benralizumab

Start the discussion